SOURCE: Symbollon Pharmaceuticals, Inc.

February 21, 2007 08:00 ET

Symbollon Pharmaceuticals Launches Web Site

FRAMINGHAM, MA -- (MARKET WIRE) -- February 21, 2007 -- Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) announced the launch of a new web site,, to increase awareness of breast pain and tenderness associated with fibrocystic breast disease. The new web site will provide detailed information regarding the condition and allow women suffering from the condition to self assess their symptoms for possible participation in Symbollon's ongoing Phase III study evaluating IoGen for the treatment of breast pain associated with fibrocystic breast disease.

Paul Desjourdy, President and CEO of Symbollon Pharmaceuticals, stated, "That the new web site should be a valuable tool for women throughout the country providing educational information to assess their condition. Symbollon believes that the internet offers a unique opportunity to attract women to its ongoing Phase III study for IoGen™ for the initial indication of breast pain associated with fibrocystic breast disease. In the site's first few weeks of existence, several women have been identified for possible inclusion in the study. We are expecting to complete patient enrollment during the first half of 2007."

About Symbollon Pharmaceuticals, Inc.

Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) is a specialty pharmaceutical company focused on the development and commercialization of proprietary drugs based on its molecular iodine technology. Symbollon is conducting a Phase III clinical trial evaluating IoGen as a potential treatment for moderate to severe periodic pain and tenderness (clinical mastalgia) associated with fibrocystic breast disease (FBD). FBD is a condition that affects approximately 20 to 33 million women in the U.S., and there are approximately 7 to 13 million women suffering from clinical periodic mastalgia. The Company believes IoGen also may be useful in treating and/or preventing endometriosis, ovarian cysts, and premenopausal breast cancer. Symbollon is also in preclinical development of antimicrobial products based on the same molecular iodine technology, and intends to investigate the potential effectiveness of its technology in applications such as dermatology, oral care, upper respiratory tract conditions, urinary tract infection and wound care. For more information about Symbollon, please visit the company's website at

Forward-Looking Statement

This news release contains statements by the Company that involve risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including, but not limited to, the risks and uncertainties associated with whether (i) future clinical trial results will support the use of IoGen for the treatment of fibrocystic breast disease, (ii) the clinical data acquired from Mimetix Inc. will be acceptable exposure data for IoGen, (iii) Symbollon will be able to obtain the resources necessary to continue as a going concern, (iv) IoGen will successfully complete the regulatory approval process, (v) competitive products will receive regulatory approval, (vi) the Company's ability to enter into new arrangements with corporate partners, (vii) the Company's partner for IoGen will be able to meet its financial obligation to pay for the IoGen clinical development and (viii) such other factors as may be disclosed from time-to-time in the Company's reports as filed with the Securities and Exchange Commission.

Contact Information

    Paul C. Desjourdy
    President and CEO
    Symbollon Pharmaceuticals, Inc.
    (508) 620-7676, x202

    Heather Kerwin
    Investor Relations
    Premier Funding & FMS
    (480) 649-8224

    37 Loring Drive
    Framingham, MA 01702
    Phone: (508) 620-7676
    Fax: (508) 620-7111